Carl‐Fredrik Burman

1.0k total citations
34 papers, 584 citations indexed

About

Carl‐Fredrik Burman is a scholar working on Statistics and Probability, Management Science and Operations Research and Economics and Econometrics. According to data from OpenAlex, Carl‐Fredrik Burman has authored 34 papers receiving a total of 584 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Statistics and Probability, 15 papers in Management Science and Operations Research and 13 papers in Economics and Econometrics. Recurrent topics in Carl‐Fredrik Burman's work include Statistical Methods in Clinical Trials (29 papers), Optimal Experimental Design Methods (15 papers) and Health Systems, Economic Evaluations, Quality of Life (13 papers). Carl‐Fredrik Burman is often cited by papers focused on Statistical Methods in Clinical Trials (29 papers), Optimal Experimental Design Methods (15 papers) and Health Systems, Economic Evaluations, Quality of Life (13 papers). Carl‐Fredrik Burman collaborates with scholars based in Sweden, United Kingdom and United States. Carl‐Fredrik Burman's co-authors include Christian Sonesson, Olivier Guilbaud, Martin Posch, Stephen Senn, Gregg W. Stone, Stuart Pocock, Linda Sharples, John Gregson, Fredrik Öhrn and Anja Schiel and has published in prestigious journals such as Journal of the American College of Cardiology, PLoS ONE and Biometrics.

In The Last Decade

Carl‐Fredrik Burman

33 papers receiving 553 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carl‐Fredrik Burman Sweden 14 366 171 143 87 56 34 584
Cornelia Dunger‐Baldauf Switzerland 13 217 0.6× 79 0.5× 117 0.8× 72 0.8× 27 0.5× 27 608
Jeff Maca United States 8 237 0.6× 107 0.6× 84 0.6× 75 0.9× 69 1.2× 16 525
Amy Racine Switzerland 10 410 1.1× 110 0.6× 216 1.5× 124 1.4× 39 0.7× 17 978
Satrajit Roychoudhury United States 15 772 2.1× 283 1.7× 183 1.3× 39 0.4× 110 2.0× 38 1.1k
Y. H. George United States 8 308 0.8× 106 0.6× 144 1.0× 22 0.3× 70 1.3× 10 420
Sandrine Micallef France 10 292 0.8× 111 0.6× 32 0.2× 28 0.3× 47 0.8× 24 678
Ping Gao China 11 195 0.5× 59 0.3× 110 0.8× 26 0.3× 28 0.5× 29 350
Elsa Valdés‐Márquez United Kingdom 11 94 0.3× 54 0.3× 50 0.3× 170 2.0× 25 0.4× 19 462
Alexei Dmitrienko United States 9 294 0.8× 96 0.6× 174 1.2× 44 0.5× 51 0.9× 25 852
Matthew M. Hutmacher United States 14 168 0.5× 52 0.3× 26 0.2× 16 0.2× 6 0.1× 31 554

Countries citing papers authored by Carl‐Fredrik Burman

Since Specialization
Citations

This map shows the geographic impact of Carl‐Fredrik Burman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carl‐Fredrik Burman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carl‐Fredrik Burman more than expected).

Fields of papers citing papers by Carl‐Fredrik Burman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carl‐Fredrik Burman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carl‐Fredrik Burman. The network helps show where Carl‐Fredrik Burman may publish in the future.

Co-authorship network of co-authors of Carl‐Fredrik Burman

This figure shows the co-authorship network connecting the top 25 collaborators of Carl‐Fredrik Burman. A scholar is included among the top collaborators of Carl‐Fredrik Burman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carl‐Fredrik Burman. Carl‐Fredrik Burman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jackson, Dan, et al.. (2024). Bayesian Solutions for Assessing Differential Effects in Biomarker Positive and Negative Subgroups. Pharmaceutical Statistics. 24(2). e2456–e2456. 1 indexed citations
2.
Burman, Carl‐Fredrik, et al.. (2024). Digital twins and Bayesian dynamic borrowing: Two recent approaches for incorporating historical control data. Pharmaceutical Statistics. 23(5). 611–629. 3 indexed citations
3.
Miller, Frank, et al.. (2023). Robust optimal designs using a model misspecification term. Metrika. 86(7). 781–804. 1 indexed citations
4.
Burman, Carl‐Fredrik, Ekkehard Glimm, Stefan M. Gold, et al.. (2022). On model-based time trend adjustments in platform trials with non-concurrent controls. BMC Medical Research Methodology. 22(1). 228–228. 30 indexed citations
5.
Gould, A. Lawrence, R. Keith Campbell, John W. Loewy, et al.. (2022). A framework for assessing the impact of accelerated approval. PLoS ONE. 17(6). e0265712–e0265712. 4 indexed citations
6.
Burman, Carl‐Fredrik, et al.. (2020). A modified weighted log-rank test for confirmatory trials with a high proportion of treatment switching. arXiv (Cornell University). 5 indexed citations
7.
Gregson, John, Linda Sharples, Gregg W. Stone, et al.. (2019). Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials. Journal of the American College of Cardiology. 74(16). 2102–2112. 51 indexed citations
8.
Hilgers, R.-D, Małgorzata Bogdan, Carl‐Fredrik Burman, et al.. (2018). Lessons learned from IDeAl — 33 recommendations from the IDeAl-net about design and analysis of small population clinical trials. Orphanet Journal of Rare Diseases. 13(1). 77–77. 24 indexed citations
9.
Miller, Frank & Carl‐Fredrik Burman. (2017). A decision theoretical modeling for Phase III investments and drug licensing. Journal of Biopharmaceutical Statistics. 28(4). 698–721. 10 indexed citations
10.
Förster, Martin, et al.. (2016). Late-stage pharmaceutical R&D and pricing policies under two-stage regulation. Journal of Health Economics. 50. 298–311. 12 indexed citations
11.
Beckman, Robert A., et al.. (2016). Optimizing Trial Designs for Targeted Therapies. PLoS ONE. 11(9). e0163726–e0163726. 19 indexed citations
12.
Lisovskaja, Vera & Carl‐Fredrik Burman. (2014). A decision theoretic approach to optimization of multiple testing procedures. Biometrical Journal. 57(1). 64–75. 2 indexed citations
13.
Burman, Carl‐Fredrik & Vera Lisovskaja. (2010). The dual test: Safeguarding p‐value combination tests for adaptive designs. Statistics in Medicine. 29(7-8). 797–807. 3 indexed citations
14.
Burman, Carl‐Fredrik, Christian Sonesson, & Olivier Guilbaud. (2009). A recycling framework for the construction of Bonferroni‐based multiple tests. Statistics in Medicine. 28(5). 739–761. 97 indexed citations
15.
Bretz, Frank, Michael Branson, Carl‐Fredrik Burman, Christy Chuang‐Stein, & Christopher S. Coffey. (2009). Adaptivity in drug discovery and development. Drug Development Research. 70(3). 169–190. 10 indexed citations
16.
Burman, Carl‐Fredrik & Christian Sonesson. (2006). Are Flexible Designs Sound?. Biometrics. 62(3). 664–669. 48 indexed citations
17.
Burman, Carl‐Fredrik, Bengt Hamrén, & Per Olsson. (2005). Modelling and simulation to improve decision-making in clinical development. Pharmaceutical Statistics. 4(1). 47–58. 16 indexed citations
18.
Malfertheiner, Peter, J Dent, L. Zeijlon, et al.. (2002). Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease — results from a randomized trial programme. Alimentary Pharmacology & Therapeutics. 16(8). 1431–1442. 61 indexed citations
19.
Burman, Carl‐Fredrik. (1996). On Sequential Treatment Allocations in Clinical Trials. Chalmers Publication Library (Chalmers University of Technology). 24 indexed citations
20.
Cullen, M.H., et al.. (1989). The role of metoclopramide in acute and delayed chemotherapy induced emesis: a randomised double blind trial. British Journal of Cancer. 60(5). 759–763. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cornelia Dunger‐Baldauf Breakdown of academic impact, for papers by Jeff Maca Breakdown of academic impact, for papers by Amy Racine Breakdown of academic impact, for papers by Satrajit Roychoudhury Breakdown of academic impact, for papers by Y. H. George Breakdown of academic impact, for papers by Sandrine Micallef Breakdown of academic impact, for papers by Ping Gao Breakdown of academic impact, for papers by Elsa Valdés‐Márquez Breakdown of academic impact, for papers by Alexei Dmitrienko Breakdown of academic impact, for papers by Matthew M. Hutmacher
Rankless by CCL
2026